Impaired glucose homeostasis in first-episode schizophrenia: A systematic review and meta-analysis

JAMA Psychiatry

Volumn 74, Issue 3, 2017, Pages 261-269

  Pillinger, Toby ^a   Beck, Katherine ^a   Gobjila, Cristian ^a   Donocik, Jacek G ^a   Jauhar, Sameer ^a   Howes, Oliver D ^a,b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); EMBASE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MEDLINE; META ANALYSIS; ORAL GLUCOSE TOLERANCE TEST; PSYCINFO; SCHIZOPHRENIA; SYSTEMATIC REVIEW; BLOOD; CASE CONTROL STUDY; DIABETES MELLITUS; HOMEOSTASIS; METABOLISM; PHYSIOLOGY; RISK;

BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; INSULIN; RISK; SCHIZOPHRENIA;

EID: 85014592133     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2016.3803     Document Type: Article

References (64)

1. Beary M, Hodgson R, Wildgust HJ. A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications. J Psychopharmacol. 2012;26 (5)(suppl):52-61.
2. Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170(3):324-333.
3. Hoang U, Goldacre MJ, Stewart R. Avoidable mortality in people with schizophrenia or bipolar disorder in England. Acta Psychiatr Scand. 2013;127 (3):195-201.
4. Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425-448.
5. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry. 2010;196(2): 116-121.
6. Osby U, Correia N, Brandt L, Ekbom A, Sparén P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000; 45(1-2):21-28.
7. De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8 (1):15-22.
8. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr Bull. 2013;39(2):306-318.
9. Maudsley H. The Pathology of Mind: A Study of Its Distempers, Deformities and Disorders. London, England: Julian Friedman Publishers; 1979.
10. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl. 2004;47:S64-S66.
11. Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016;15(2):166-174.
12. Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? a comparativemeta-analysis of first episode, untreated and treated patients. Schizophr Bull. 2013;39(2):295-305.
13. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006-1012.
14. Stroup DF, Berlin JA, Morton SC, et al; Meta-analysis of Observational Studies in Epidemiology (MOOSE) Group. Meta-analysis of Observational Studies in Epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008-2012.
15. Miller TJ, McGlashan TH, Woods SW, et al. Symptom assessment in schizophrenic prodromal states. Psychiatr Q. 1999;70(4):273-287.
16. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005;39(11-12):964-971.
17. Breitborde NJ, Srihari VH, Woods SW. Review of the operational definition for first-episode psychosis. Early Interv Psychiatry. 2009;3(4): 259-265.
18. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2003;26(suppl 1):S5-S20.
19. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation; Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, Switzerland:World Health Organization; 1999.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7): 412-419.
21. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998; 21(12):2191-2192.
22. Roglic G; World Health Organization. Global Report on Diabetes. Geneva, Switzerland:World Health Organization; 2016.
23. Stubbs B, Firth J, Berry A, et al. How much physical activity do people with schizophrenia engage in? a systematic review, comparative meta-analysis and meta-regression. Schizophr Res. 2016;176(2-3):431-440.
24. Juutinen J, Hakko H, Meyer-Rochow VB, Räsänen P, Timonen M; Study-70 Research Group. Body mass index (BMI) of drug-naïve psychotic adolescents based on a population of adolescent psychiatric inpatients. Eur Psychiatry. 2008;23(7): 521-526.
25. Koivukangas J, Tammelin T, Kaakinen M, et al. Physical activity and fitness in adolescents at risk for psychosis within the Northern Finland 1986 Birth Cohort. Schizophr Res. 2010;116(2-3):152-158.
26. Zhang XY, Chen DC, Tan YL, et al. Glucose disturbances in first-episode drug-naïve schizophrenia: relationship to psychopathology. Psychoneuroendocrinology. 2015;62:376-380.
27. Petrikis P, Tigas S, Tzallas AT, Papadopoulos I, Skapinakis P, Mavreas V. Parameters of glucose and lipid metabolism at the fasted state in drug-naïve first-episode patients with psychosis: evidence for insulin resistance. Psychiatry Res. 2015;229(3): 901-904.
28. Enez Darcin A, Yalcin Cavus S, Dilbaz N, Kaya H, Dogan E. Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings. Schizophr Res. 2015;166(1-3):201-206.
29. Dasgupta A, Singh OP, Rout JK, Saha T, Mandal S. Insulin resistance and metabolic profile in antipsychotic naïve schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7): 1202-1207.
30. Arranz B, Rosel P, Ramírez N, et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry. 2004;65(10):1335-1342.
31. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003; 160(2):284-289.
32. Venkatasubramanian G, Chittiprol S, Neelakantachar N, et al. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry. 2007;164(10): 1557-1560.
33. Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry. 2006;51(6):382-386.
34. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med. 2007;24(5):481-485.
35. Wani RA, Dar MA, Margoob MA, Rather YH, Haq I, Shah MS. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia, before and after antipsychotic treatment. J Neurosci Rural Pract. 2015;6(1):17-22.
36. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Diabetes and schizophrenia-effect of disease or drug? results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand. 2008;117(5):342-347.
37. Garcia-Rizo C, Kirkpatrick B, Fernandez-Egea E, Oliveira C, Bernardo M. Abnormal glycemic homeostasis at the onset of serious mental illnesses: a common pathway. Psychoneuroendocrinology. 2016;67:70-75.
38. Sengupta S, Parrilla-Escobar MA, Klink R, et al. Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls? Schizophr Res. 2008;102(1-3):329-336.
39. Chen S, Broqueres-You D, Yang G, et al. Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia. Psychiatry Res. 2013;210(3):825-829.
40. Sun HQ, Li SX, Chen FB, et al. Diurnal neurobiological alterations after exposure to clozapine in first-episode schizophrenia patients. Psychoneuroendocrinology. 2016;64:108-116.
41. Fernandez-Egea E, Bernardo M, Donner T, et al. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry. 2009; 194(5):434-438.
42. Bowden J, Tierney JF, Copas AJ, Burdett S. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol. 2011;11:41.
43. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency inmeta-analyses. BMJ. 2003;327(7414):557-560.
44. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
45. Higgins JPT, Green S. Cochrane Collaboration: Cochrane Handbook for Systematic Reviews of Interventions. Chichester, England; Wiley-Blackwell; 2008.
46. Chen DC, Du XD, Yin GZ, et al. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits. Psychol Med. 2016;46(15):3219-3230.
47. Myles N, Newall HD, Curtis J, Nielssen O, Shiers D, Large M. Tobacco use before, at, and after first-episode psychosis: a systematic meta-analysis. J Clin Psychiatry. 2012;73(4):468-475.
48. St Clair D, Xu M, Wang P, et al. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. JAMA. 2005;294(5): 557-562.
49. Xu MQ, Sun WS, Liu BX, et al. Prenatal malnutrition and adult schizophrenia: further evidence from the 1959-1961 Chinese famine. Schizophr Bull. 2009;35(3):568-576.
50. Susser ES, Lin SP. Schizophrenia after prenatal exposure to the Dutch Hunger Winter of 1944-1945. Arch Gen Psychiatry. 1992;49(12):983-988.
51. Ravelli AC, van der Meulen JH, Michels RP, et al. Glucose tolerance in adults after prenatal exposure to famine. Lancet. 1998;351(9097):173-177.
52. Borges S, Gayer-Anderson C, Mondelli V. A systematic review of the activity of the hypothalamic-pituitary-adrenal axis in first episode psychosis. Psychoneuroendocrinology. 2013;38(5): 603-611.
53. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet. 1989;1(8636):495.
54. Foley DL, Mackinnon A, Morgan VA, et al. Common familial risk factors for schizophrenia and diabetes mellitus. Aust N Z J Psychiatry. 2016;50(5): 488-494.
55. van Welie H, Derks EM, Verweij KH, de Valk HW, Kahn RS, Cahn W. The prevalence of diabetes mellitus is increased in relatives of patients with a non-affective psychotic disorder. Schizophr Res. 2013;143(2-3):354-357.
56. Lin PI, Shuldiner AR. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res. 2010;123(2-3):234-243.
57. Liu Y, Li Z, Zhang M, Deng Y, Yi Z, Shi T. Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis. BMC Med Genomics. 2013;6(suppl 1):S17.
58. Tai ES, Lim SC, Tan BY, Chew SK, Heng D, Tan CE. Screening for diabetes mellitus-a two-step approach in individuals with impaired fasting glucose improves detection of those at risk of complications. Diabet Med. 2000;17(11):771-775.
59. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care. 2009;32(suppl 1):S13-S61.
60. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia: Report of a WHO/IDF Consultation. Geneva, Switzerland:World Health Organization; 2006.
61. van Winkel R, De Hert M, Van Eyck D, et al. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screeningmethods. J Clin Psychiatry. 2006;67 (10):1493-1500.
62. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27 (6):1487-1495.
63. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59(4):337-345.
64. Howes OD, Bhatnagar A, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry. 2004;161(2):361-363.